DC CFAR investigator and Clinical and Population Sciences (CPS) Core Director Princy Kumar, MD, along with her colleagues, has published an article in The New England Journal of Medicine entitled, "Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1".
This article discusses a phase 3 study conducted to assess the effectiveness of Ibalizumab - a humanized IgG4 monoclonal antibody that blocks the entry of human immunodeficiency virus type 1 (HIV-1) by noncompetitive binding to CD4 - in treating adults with multidrug-resistant (MDR) HIV-1 infection in whom multiple antiretroviral therapies had failed. Results included that at week 25 of the study, patients in the group receiving ibalizumab plus an optimized background regimen had a mean decrease of 1.6 log10 copies per milliliter from baseline; 43% of the patients had a viral load of less than 50 copies per milliliter, and 50% had a viral load of less than 200 copies per milliliter.
Click here to read the full article.